S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Bicycle Therapeutics Stock Forecast, Price & News

-0.32 (-0.58%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
79,959 shs
Average Volume
197,377 shs
Market Capitalization
$1.61 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BCYC News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Bicycle Therapeutics logo

About Bicycle Therapeutics

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.


SM celebrates National Bicycle Day
November 25, 2021 |  msn.com
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Down to $58.13
November 22, 2021 |  americanbankingnews.com
Bicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month High at $61.64
November 15, 2021 |  americanbankingnews.com
Analyzing Ainos (OTCMKTS:AIMD) & Bicycle Therapeutics (NASDAQ:BCYC)
November 3, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$10.39 million
Book Value
$5.81 per share


Net Income
$-51.01 million
Net Margins
Pretax Margin




Free Float
Market Cap
$1.61 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.20 out of 5 stars

Medical Sector

368th out of 1,391 stocks

Pharmaceutical Preparations Industry

167th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Bicycle Therapeutics (NASDAQ:BCYC) Frequently Asked Questions

Is Bicycle Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bicycle Therapeutics stock.
View analyst ratings for Bicycle Therapeutics
or view top-rated stocks.

How has Bicycle Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Bicycle Therapeutics' stock was trading at $17.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BCYC shares have increased by 208.5% and is now trading at $54.60.
View which stocks have been most impacted by COVID-19

Are investors shorting Bicycle Therapeutics?

Bicycle Therapeutics saw a increase in short interest in October. As of October 29th, there was short interest totaling 443,400 shares, an increase of 44.5% from the October 14th total of 306,900 shares. Based on an average daily volume of 319,300 shares, the days-to-cover ratio is currently 1.4 days.
View Bicycle Therapeutics' Short Interest

When is Bicycle Therapeutics' next earnings date?

Bicycle Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Bicycle Therapeutics

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) released its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.02. The firm earned $4.33 million during the quarter, compared to analysts' expectations of $5.29 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 48.12% and a negative net margin of 562.38%.
View Bicycle Therapeutics' earnings history

What price target have analysts set for BCYC?

8 Wall Street analysts have issued 1-year price targets for Bicycle Therapeutics' stock. Their forecasts range from $58.00 to $85.00. On average, they anticipate Bicycle Therapeutics' share price to reach $68.25 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts' price targets for Bicycle Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bicycle Therapeutics' key executives?

Bicycle Therapeutics' management team includes the following people:

What other stocks do shareholders of Bicycle Therapeutics own?

When did Bicycle Therapeutics IPO?

(BCYC) raised $64 million in an IPO on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Bicycle Therapeutics' stock symbol?

Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC."

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.93%), Point72 Asset Management L.P. (5.80%), AXA S.A. (0.71%), Verition Fund Management LLC (0.64%), Victory Capital Management Inc. (0.53%) and Morgan Stanley (0.52%). Company insiders that own Bicycle Therapeutics stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander.
View institutional ownership trends for Bicycle Therapeutics

Which major investors are selling Bicycle Therapeutics stock?

BCYC stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Janus Henderson Group PLC, Verition Fund Management LLC, Victory Capital Management Inc., Laurion Capital Management LP, Moody Aldrich Partners LLC, Advisor Group Holdings Inc., and Parkman Healthcare Partners LLC. Company insiders that have sold Bicycle Therapeutics company stock in the last year include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, and Stephen B Alexander.
View insider buying and selling activity for Bicycle Therapeutics
or view top insider-selling stocks.

Which major investors are buying Bicycle Therapeutics stock?

BCYC stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Altium Capital Management LP, Morgan Stanley, Bellevue Group AG, Two Sigma Advisers LP, Jump Financial LLC, Goldman Sachs Group Inc., and Woodstock Corp.
View insider buying and selling activity for Bicycle Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bicycle Therapeutics' stock price today?

One share of BCYC stock can currently be purchased for approximately $54.60.

How much money does Bicycle Therapeutics make?

Bicycle Therapeutics has a market capitalization of $1.61 billion and generates $10.39 million in revenue each year. The company earns $-51.01 million in net income (profit) each year or ($2.89) on an earnings per share basis.

How many employees does Bicycle Therapeutics have?

Bicycle Therapeutics employs 2,020 workers across the globe.

What is Bicycle Therapeutics' official website?

The official website for Bicycle Therapeutics is www.bicycletherapeutics.com.

Where are Bicycle Therapeutics' headquarters?

Bicycle Therapeutics is headquartered at B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT.

How can I contact Bicycle Therapeutics?

Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The company can be reached via phone at 441223261503.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.